The Biosimilar Roundup

As we are just entering July, the month of June saw new updates and developments in the world of biosimilars for rheumatology, according to The Center for Biosimilars. 

The report stated that two more biosimilars received positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of inflammatory disease: trastuzumab and adalimumab.  

The EULAR congress also featured data on switching patients to etanercept and infliximab, and that using tofacitinib as second-line treatment after methotrexate could be a more cost-effective approach than initiating and cycling anti-TNF therapies. 

SOURCE: The Center for Biosimilars